How AI4S Re-rates the CXO: Novo Nordisk × Anthropic, Anew Labs' US$290M Raise, and the Wet-Lab Loop Driving Fresh Outsourcing Demand

AI for Science (AI4S) is moving from concept to industrialization and, through the 'dry-wet loop', directly drives demand for CXO and research upstream. Novo Nordisk teams with Anthropic, ByteDance's Anew Labs raises US$290M, and Danaher and Biohub together commit over US$1.8B to AI bio-data infrastructure — AI drug discovery is becoming a third force reshaping CDMO order structure.

A new thread is forming in the pharma sector in H2 2026: AI for Science (AI4S), represented by generative AI, is moving from concept to industrialization and, through the 'dry-wet loop', directly drives demand for CXO and research upstream. From Novo Nordisk teaming with Anthropic, to ByteDance's Anew Labs raising US$290M and Danaher and Biohub together committing over US$1.8B to AI bio-data infrastructure, AI drug discovery is becoming a third force — after ADCs and GLP-1 — reshaping CDMO order structure.

1. Capital and giants bet collectively on AI bio-infrastructure

In early October, Danaher and Biohub each announced plans for in-house AI labs and a US$1.8B commitment to building AI bio-data infrastructure, signaling that industrial capital now treats AI capability as next-generation R&D infrastructure. Meanwhile Novo Nordisk announced a partnership with Anthropic to bring frontier large-model capability into its drug-development workflow; ByteDance-incubated Anew Labs closed a US$290M raise on a next-generation 'dry-wet loop' drug-discovery platform.

The signal is clear: AI is no longer just an auxiliary tool but is restructuring the 'hypothesis generation — experimental validation — data feedback' R&D loop, and every loop needs real wet-lab and scaled synthesis capacity to close.

2. ESMO 2026 and the quarterly window: Chinese innovative drugs deliver data densely

Broker notes point out that the pharma sector is meeting a double window of Q3 earnings validation and ESMO 2026 global data release. Multiple domestic ADC and IO 2.0 (next-generation immuno-oncology) products posted positive overall-survival (OS) results in international Phase 3 trials, with Chinese studies taking 5 seats in the ESMO Presidential Symposium — continuously validating the global competitiveness of China's innovative drugs. Dense data delivery in turn lifts downstream clinical and commercial-stage outsourcing demand.

3. How AI4S converts into CDMO orders

AI4S drives CXO demand on two levels. On 'volume': AI accelerates the output of hit compounds and candidates, meaning more molecules need synthesis, screening, process development and scale-up — directly benefiting small-molecule CRDMO and high-throughput screening / safety-assessment CROs. On 'quality': AI-designed molecules often point to more complex architectures (e.g., PROTACs, molecular glues, peptide conjugates) with higher synthesis and CMC difficulty and higher unit value, creating incremental orders for players with complex-molecule platforms (WuXi AppTec TIDES, Asymchem chemical macromolecules, WuXi XDC conjugates).

4. Policy and valuation: allocation value stands out

The 15th Five-Year Plan targets First-in-class drugs at >25% of the global total by 2030, shifting policy from cost control toward supporting original innovation, with AI+drug-discovery named a key direction. On valuation, the pharma sector trades at ~29.5x PE, below its historical mean, with active-fund pharma overweight at only ~6.6% — allocation value is prominent. Broker notes list WuXi AppTec, Pharmaron, Insilico Medicine, HitGen and Crystal (晶泰控股) as intersection names between AI drug discovery and CXO.

AI4S is not a replacement for the CXO but an amplifier: it raises the 'imagination' of drug discovery while pushing more, more complex molecules downstream to wet labs and capacity. For CRDMOs, whoever can catch the high-complexity molecules AI generates and close the loop efficiently will capture this compute-driven outsourcing increment.